ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag stock market immunology culture

SinoBiological Red Logo
Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange
Sino Biological | Aug 17, 2021 | 2 min read
Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were issued for a total of 4.98 billion RMB raised during this initial public offering.
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
An illustration of flowers in the shape of the female reproductive tract
Uterus Transplants Hit the Clinic
Jef Akst | Aug 1, 2021 | 10+ min read
With human research trials resulting in dozens of successful deliveries in the US and abroad, doctors move toward offering the surgery clinically, while working to learn all they can about uterine and transplant biology from the still-rare procedure.
Better Understanding Of Cell's Life Eases Culturing
Ricki Lewis | Nov 13, 1994 | 10+ min read
"Lots of companies come out with media or reagents for this or that, and make a big splash, but they're all basically derivatives of traditional products," says Hayden Coon, a former National Institutes of Health re-searcher who is the founder of Human Cell Therapies Inc. of Chebeague Island, Maine. Advanced Biotechnologies Inc. Columbia, MD American Qualex Antibodies La Mirada, CA American Type Culture Collection (ATCC) Rockv
Better Understanding Of Cell's Life Eases Culturing
Ricki Lewis | Nov 13, 1994 | 10+ min read
"Lots of companies come out with media or reagents for this or that, and make a big splash, but they're all basically derivatives of traditional products," says Hayden Coon, a former National Institutes of Health re-searcher who is the founder of Human Cell Therapies Inc. of Chebeague Island, Maine. Advanced Biotechnologies Inc. Columbia, MD American Qualex Antibodies La Mirada, CA American Type Culture Collection (ATCC) Rockv
It's all about Cells
Miltenyi Biotec | Jan 12, 2009 | 2 min read
It's all about cells Miltenyi Biotec products and services benefit the biomedical research community worldwide In 1989, a success story began in Bergisch Gladbach near Cologne: MACS® Technology was developed, an efficient and reliable method to tag and separate cells magnetically. Since then, the Miltenyi Biotec team has grown to more than 1,100 employees. They produce and market over 1,400 products for the biomedical research community worldwide,
Two Distinct Career Paths Offer Clear Choices
James Kling | Jul 5, 1998 | 6 min read
Big Pharma: Big markets. Traditional science. Big future and lofty salaries. Biotech: Lots of competition for smaller markets. Cutting-edge science. Iffy future, but tempting stock options. Such are the widely held perceptions regarding the industry sectors that employ life science researchers. Those perceptions have become clichés, and like all great clichés, they're not altogether accurate--but they do contain a kernel of truth. The real truth is, the maturing biotech industr
Making Things Grow: Insect Cells, Stem Cells, and Primary Cell Lines All Pose Challenges for Cell Culturists
Laura Defrancesco | Jun 21, 1998 | 5 min read
Date: June 22, 1998 Insect Cell Culture Media, Suppliers of Primary Cell Culture Media Advantages for Protein Expression Studies Since the mid-1950s cultures of insects--cockroaches, fruit flies, and leafhoppers, to name a few--have been the object of quiet study by physiologists and cell biologists. But along came genetic engineering and suddenly insect cultures have been put in the spotlight since they provide advantages over both bacterial and mammalian systems for recombinant protein prod
Genentech Builds a Blockbuster-free Road to Billions
Susan Warner | Jun 6, 2004 | 8 min read
Courtesy of GenentechGenentech, the first US biotechnology company, has survived ugly patent disputes, product flops, and a Big Pharma partnership to become the biotech every company wants to be. The stock market value of the company, which makes the cancer drugs Herceptin and Rituxan, rose $7 billion (US), or 12%, in a single day in April based on promising data for a new lung-cancer treatment, Tarceva. That jump came less than a year after good results for Avastin in colon cancer trials sent t
a mockup of an at-home COVID-19 test in development
Top Technical Advances of 2020
Shawna Williams | Dec 18, 2020 | 3 min read
The pandemic spurred innovation in a variety of ways, from CRISPR-based diagnostics to cell biology benchwork at home.

Run a Search

ADVERTISEMENT